Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors | Synapse
October 8, 2025Open Access
Table 4 from A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors
Key Points
Patients experienced stable disease while receiving basroparib, indicating possible effectiveness.
The study involves analyzing data from patients with advanced-stage solid tumors treated with basroparib.
This phase I study focuses on dose escalation in assessing safety and initial effectiveness of the tankyrase inhibitor.
The findings highlight the need for further research into basroparib's potential in treating these tumors.